155 related articles for article (PubMed ID: 36066242)
1. Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.
Gathirua-Mwangi W; Yang T; Khan T; Wu Y; Afable M
Future Oncol; 2022 Sep; 18(29):3299-3310. PubMed ID: 36066242
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
4. Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study.
Yang TS; Chen HH; Bo-Wen L; Kim TW; Kim JG; Ahn JB; Lee MA; Lin J; Ho GF; Anh LT; Temraz S; Burge M; Chua C; Huang J; Park YS
Asia Pac J Clin Oncol; 2023 Dec; 19(6):672-680. PubMed ID: 36855017
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
6. Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Fukuda K; Osumi H; Yoshino K; Nakayama I; Fukuoka S; Ogura M; Wakatsuki T; Ooki A; Takahari D; Chin K; Yamaguchi K; Shinozaki E
BMC Cancer; 2023 Jul; 23(1):634. PubMed ID: 37415118
[TBL] [Abstract][Full Text] [Related]
7. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study].
Duan JJ; Ning T; Bai M; Zhang L; Li HL; Liu R; Ge SH; Wang X; Yang YC; Ji Z; Wang FX; Sun YS; Ba Y; Deng T
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):967-972. PubMed ID: 37968083
[No Abstract] [Full Text] [Related]
9. Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
Xu R; Wang W; Zhu B; Lin X; Ma D; Zhu L; Zhao Q; Nie Y; Cai X; Li Q; Fang W; Li H; Wang N; Chen Y; Peng C; Fang H; Shen L
BMC Cancer; 2020 Feb; 20(1):131. PubMed ID: 32070312
[TBL] [Abstract][Full Text] [Related]
10. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Folprecht G; Hamann S; Schütte K; Trarbach T; Stoehlmacher-Williams J; Ehninger G
BMC Cancer; 2014 Jul; 14():521. PubMed ID: 25038824
[TBL] [Abstract][Full Text] [Related]
11. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Raoul JL; Van Laethem JL; Peeters M; Brezault C; Husseini F; Cals L; Nippgen J; Loos AH; Rougier P
BMC Cancer; 2009 Apr; 9():112. PubMed ID: 19366444
[TBL] [Abstract][Full Text] [Related]
14. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
15. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Zhang T; Su D; Li J; Wang Y; Han C; Jiao S; Bai L
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Jun; 18(6):584-8. PubMed ID: 26108774
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit.
Tampellini M; Di Maio M; Baratelli C; Anania L; Brizzi MP; Sonetto C; La Salvia A; Scagliotti GV
Clin Colorectal Cancer; 2017 Dec; 16(4):372-376. PubMed ID: 28465170
[TBL] [Abstract][Full Text] [Related]
20. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
